Immunomedics (IMMU) develops antibody-based medical products used to detect, diagnose and treat cancer. The Company is particularly focused on developing products in the following areas: in-vitro diagnostic tests for the detection of cancer and certain autoimmune diseases; in-vivo imaging products for the early detection and diagnosis of cancer using a method called radioimmunodetection; in-vivo therapeutic products used in the targeted delivery of therapeutic doses of radioisotopes colorectal and gastrointestinal cancer tissues.
Address
300 The American Road
MORRIS PLAINS, NJ 07950
United States
MORRIS PLAINS, NJ 07950
United States
Website links
www.immunomedics.comKey stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 474.35% | 2.13% |
| Operating margin | 472.33% | 2.67% |
| EBITD margin | - | 7.24% |
| Return on average assets | 81.11% | 1.91% |
| Return on average equity | 103.13% | 2.71% |
| Employees | 124 |
No comments:
Post a Comment